Hepatocellular CarcinomaPhase 1NCT05003895
CAR-T cell
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
What the film says
Fibrolamellar carcinoma is a rare liver cancer that mostly affects adolescents and young adults, and few drug treatments have proven benefit.
The idea: add an immune-stimulating antibody to chemotherapy and interferon. Fluorouracil is given by vein and interferon alpha 2b by injection for two cycles. Then nivolumab, an antibody that may help the immune system attack the cancer, is added.
The first question is safety. The study then looks at how tumors respond, compared with earlier patients treated at the same hospital. At MD Anderson in Houston, Sunyoung Lee leads it, for cancer that cannot be removed by surgery.
Public record; not medical advice.
Sources behind this film
O'Neill AF. Curr Probl Cancer, 2021
Rare liver cancer, mostly adolescents and young adults; few proven drug treatments
Fluorouracil by vein, interferon alpha 2b by injection for two cycles, then nivolumab added; Nivolumab may help the immune system attack the cancer; First question is safety; then response, compared with earlier patients at the same hospital; MD Anderson, Houston; Sunyoung Lee; cannot be removed by surgery
The drug
PRIMARY OBJECTIVE: I. To evaluate the safety and tolerability of therapy with nivolumab + fluorouracil (5-FU) + recombinant interferon alpha 2b-like protein (IFN-alpha2b) in patients with unresectable fibrolamellar hepatocellular carcinoma (FLHCC) in the context of palliative systemic and prebiopsy therapy. SECONDARY OBJECTIVE: I.
To assess the efficacy of nivolumab + 5-FU + IFN-alpha2b therapy in patients with unresectable FLHCC by estimating the overall response rate (ORR) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, and comparing those rates to those from historical controls in our published data. EXPLORATORY OBJECTIVES: I.
The study
This phase I/II trial studies the side effects and how well nivolumab, fluorouracil, and interferon alpha 2b work for the treatment of fibrolamellar cancer (liver cell cancer) that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread.
Chemotherapy drugs, such as fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Interferon alpha 2b may help stimulate the immune system to fight cancer. Giving nivolumab, fluorouracil, and interferon alpha 2b may work better in treating unresectable fibrolamellar cancer compared to fluorouracil and interferon alpha 2b alone.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.